295 related articles for article (PubMed ID: 34485125)
1. Recent Progress on Primary Central Nervous System Lymphoma-From Bench to Bedside.
Shao L; Xu C; Wu H; Jamal M; Pan S; Li S; Chen F; Yu D; Liu K; Wei Y
Front Oncol; 2021; 11():689843. PubMed ID: 34485125
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
Shen J; Liu J
Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases.
Liu Y; Sun J; Tuo K
Case Rep Oncol; 2023; 16(1):227-233. PubMed ID: 37069896
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.
Bai SJ; He JX; Zheng YJ; Geng Y; Gao YN; Zhang CX; Wang YR; Qin LY; Wang WJ; Yang LH
Ann Hematol; 2024 May; ():. PubMed ID: 38761184
[TBL] [Abstract][Full Text] [Related]
6. Update on Novel Therapeutics for Primary CNS Lymphoma.
Schaff LR; Grommes C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771535
[TBL] [Abstract][Full Text] [Related]
7. Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.
Cheng Q; Wang J; Lv C; Xu J
Onco Targets Ther; 2021; 14():3367-3372. PubMed ID: 34079282
[TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
10. Primary CNS lymphoma: update on molecular pathogenesis and therapy.
Mo SS; Cleveland J; Rubenstein JL
Leuk Lymphoma; 2023 Jan; 64(1):57-65. PubMed ID: 36286546
[TBL] [Abstract][Full Text] [Related]
11. [Primary central nervous system lymphoma: advances in treatment strategies].
Kondo E
Rinsho Ketsueki; 2020; 61(5):510-519. PubMed ID: 32507817
[TBL] [Abstract][Full Text] [Related]
12. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of primary central nervous system lymphoma.
Han CH; Batchelor TT
Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging therapies for primary central nervous system lymphoma.
Yuan Y; Ding T; Wang S; Chen H; Mao Y; Chen T
Biomark Res; 2021 May; 9(1):32. PubMed ID: 33957995
[TBL] [Abstract][Full Text] [Related]
15. Targeting Bruton's tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study.
Guan W; Wang L; Peng X
Exp Hematol Oncol; 2022 Nov; 11(1):95. PubMed ID: 36348442
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
[TBL] [Abstract][Full Text] [Related]
18. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
19. Challenges and opportunities in primary CNS lymphoma: A systematic review.
Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
[TBL] [Abstract][Full Text] [Related]
20. Updates of primary central nervous system lymphoma.
Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
